Toxicity is extremely rare, but injections should still be given under professional guidance
Upon adenosine diphosphate (ADP) activation, the P2RY12 receptor interacts with Gi and inhibits adenylate cyclase activity (168)
Sharma V, Kumar B, Saxena R
PMID: 8875519 Cinar V, Polat Y, Baltaci AK, Mogulkoc R
GHK-Cu dosage in clinical and research contexts typically ranges from 0.5 to 3 mg administered monthly via subcutaneous injection, though individual protocols vary based on treatment goals and baseline health markers
While more canine-specific research is needed, what we know so far paints an optimistic picture